第一线尼沃卢马布加上伊皮利穆马布在多间皮瘤中:来自现实世界MesoNet研究的有效性和安全性数据
Rajiv Shah1, Eva L Buchmeier2, Hans-Georg Kopp3
1Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership between DKFZ and Heidelberg University Hospital, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Lung cancer (Amsterdam, Netherlands)
|August 8, 2025
概括
肺间皮瘤的第一线尼沃卢马布/伊皮利穆马布显示,现实世界的生存率与符合条件的患者的临床试验相当. 免疫相关的不良事件,尤其是低度的不良事件,与改善的结果相关.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部癌症 胸部癌症 乳腺癌
背景情况:
- 尽管尼沃卢马布/伊皮利穆马布已获得批准,但多间皮质瘤 (PM) 的预后不佳.
- 检查Mate (CM) -743试验证明了这种组合的生存率有所改善,但现实数据有限.
研究的目的:
- 评价一线尼沃卢马布/伊皮利穆马布在多间皮瘤患者的实际结果和安全性.
- 将现实数据与具有里程碑意义的CM-743试验结果进行比较.
主要方法:
- 这是一项回顾性多中心研究,对135名接受一线尼沃卢马布/伊皮利穆马布治疗的患者进行了回顾性研究.
- 来自德国12个癌症中心的结果和安全数据的分析.
- 根据修订的RECIST标准评估的放射性反应.
主要成果:
- 在未被选择的队列中,平均整体存活时间 (OS) 为13.1个月,在CM-743合格患者中为15.5个月.
- 部分反应与显著更长的生存时间相关 (24个月 vs 10.3个月).
- 与免疫相关的不良事件 (irAEs) 与更长的存活时间有关 (17.3个月与11.7个月),低级的irAEs显示出最好的结果.
结论:
- 对于符合条件的患者,特别是非上皮状子类型的患者,nivolumab/ipilimumab的现实生存率与CM-743相当.
- 低等级的IRAE与优异的结果有关,这表明它们作为预测标记物的潜力.
- 双重检查点封锁和-pemetrexed化疗是PM的可行的一线选择.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:30Pleural Disorders: Types and Brief Description
294
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
294